EEG Entropy Rises in Vegetative-State Patients During Hyperbaric Oxygen Therapy, Study Finds

Abstract visualization of EEG brainwave complexity mapping over a hyperbaric oxygen chamber environment

For families of patients trapped in vegetative or minimally conscious states, any signal of awareness can feel like a lifeline. A new study from Hefei Second People’s Hospital and Anhui Medical University in China suggests that hyperbaric oxygen therapy (HBOT) may produce measurable shifts in brain electrical activity that track alongside behavioral improvements in this population. The findings, published September 24 in Neurological Sciences, add a rare electrophysiological dimension to the debated question of whether pressurized oxygen can coax injured brains back toward consciousness.

Quantifying the Flickers of Awareness

The researchers retrospectively analyzed 40 patients with prolonged disorders of consciousness (PDOC), a category that spans the vegetative state and the minimally conscious state. All had received a 20-session course of HBOT at 2.0 atmospheres absolute, and each underwent repeated assessments with the Coma Recovery Scale-Revised (CRS-R), the clinical gold standard for detecting signs of consciousness. Crucially, the team also recorded resting-state quantitative electroencephalography (qEEG) at three time points: before treatment, during the first session, and during the twentieth session.

Rather than simply eyeballing waveforms, the investigators applied three computational metrics. Power spectral density captured the distribution of energy across frequency bands. Permutation entropy and Lempel-Ziv complexity measured the unpredictability and information richness of the EEG signal—properties that tend to collapse when consciousness fades and expand when it returns.

The results were striking. Permutation entropy and Lempel-Ziv complexity rose progressively and significantly across every brain region in both higher-functioning and lower-functioning patients. In the frontal cortex of patients who entered the study with CRS-R scores of 8 or above, permutation entropy climbed from 0.37 to 0.66 over the course; in the more impaired group, it moved from 0.37 to 0.62. Complexity metrics followed a similar arc. Clinically, mean CRS-R scores improved from 6.3 to 8.7 across the full cohort, with both subgroups showing gains. Power spectral density remained largely stable, except for a theta-band shift in the occipital region of the lower-scoring patients.

The authors are careful to note that the EEG changes occurred “in parallel” with the clinical improvements, but they did not formally test for correlation. Whether the qEEG shifts predict recovery, or merely accompany it, remains an open question.

A Missing Control Group

The study’s biggest limitation is its design. It is a retrospective, self-controlled series, meaning each patient served as his or her own baseline. There was no sham-HBOT arm, no randomization, and no blinding. In the world of consciousness research, where spontaneous fluctuations and placebo-like responses are well documented, that absence matters. The authors explicitly acknowledge that “causal or predictive inference awaits controlled studies.”

That caution is especially relevant given the history of HBOT in neurorehabilitation. Over the past two decades, trials in traumatic brain injury and stroke have produced inconsistent results, with some studies showing functional gains and others finding no separation from sham compression. The Department of Veterans Affairs and the Department of Defense have funded multiple investigations into HBOT for TBI and PTSD, including the HOPPS trial, which ultimately reported no benefit over sham. The National Institutes of Health is currently enrolling the HOBIT trial, a Phase II study of HBOT for severe TBI, but results are not expected for years.

The FDA’s Position

The U.S. Food and Drug Administration has not cleared HBOT for disorders of consciousness, traumatic brain injury, stroke, or any other neurological indication outside of its established list. The agency’s cleared indications remain confined to conditions such as decompression sickness, carbon monoxide poisoning, certain non-healing diabetic wounds, late radiation tissue injury, gas gangrene, severe anemia, selected skin grafts and flaps, crush injury, thermal burns, idiopathic sudden sensorineural hearing loss, and intracranial abscess.

In August 2025, the FDA issued a safety letter to health care providers warning of fire risks, injuries, and deaths associated with HBOT devices, and reminding clinicians that off-label use in unproven indications carries unquantified hazards. For families considering HBOT for a loved one in a vegetative state, that regulatory stance is a critical piece of context: the therapy is experimental in this setting, not standard of care.

Why EEG Complexity Matters

If the Chinese findings hold up in controlled work, they could offer something the field has long lacked: an objective, bedside biomarker of treatment response. Behavioral assessments in PDOC are notoriously noisy, vulnerable to examiner bias, fatigue, and day-to-day variability. A reliable qEEG signature would give clinicians a parallel channel of evidence, helping to distinguish true biological change from wishful thinking.

The study also fits into a broader mechanistic narrative. HBOT is thought to reduce neuroinflammation, promote angiogenesis, and improve mitochondrial efficiency in hypoxic tissue—all processes that could theoretically support neural repair after severe brain injury. Whether those molecular effects actually translate into recovered consciousness is the billion-dollar question that only rigorous trials can answer.

For now, the data are suggestive but not definitive. The brain-complexity signals are real, the clinical gains are documented, and the absence of a control group means neither can be confidently attributed to the oxygen itself.

Sources

← Back to blog